GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Echo Therapeutics Inc (OTCPK:ECTE) » Definitions » Equity-to-Asset

Echo Therapeutics (Echo Therapeutics) Equity-to-Asset : -5.84 (As of Sep. 2016)


View and export this data going back to 1997. Start your Free Trial

What is Echo Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Echo Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2016 was $-6.29 Mil. Echo Therapeutics's Total Assets for the quarter that ended in Sep. 2016 was $1.08 Mil.

The historical rank and industry rank for Echo Therapeutics's Equity-to-Asset or its related term are showing as below:

ECTE's Equity-to-Asset is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.65
* Ranked among companies with meaningful Equity-to-Asset only.

Echo Therapeutics Equity-to-Asset Historical Data

The historical data trend for Echo Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Echo Therapeutics Equity-to-Asset Chart

Echo Therapeutics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.87 0.51 0.84 0.76 -3.14

Echo Therapeutics Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.43 -3.14 -4.84 -3.94 -5.84

Competitive Comparison of Echo Therapeutics's Equity-to-Asset

For the Medical Devices subindustry, Echo Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Echo Therapeutics's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Echo Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Echo Therapeutics's Equity-to-Asset falls into.



Echo Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Echo Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2015 is calculated as

Equity to Asset (A: Dec. 2015 )=Total Stockholders Equity/Total Assets
=-2.526/0.805
=

Echo Therapeutics's Equity to Asset Ratio for the quarter that ended in Sep. 2016 is calculated as

Equity to Asset (Q: Sep. 2016 )=Total Stockholders Equity/Total Assets
=-6.286/1.077
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Echo Therapeutics  (OTCPK:ECTE) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Echo Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Echo Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Echo Therapeutics (Echo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
99 Wood Avenue South, Suite 302, Iselin, NJ, USA, 08830
Echo Therapeutics Inc is a medical device company with expertise in skin permeation technology. It develops non-invasive, wireless continuous glucose monitoring system with potential use in the wearable health consumer and the diabetes outpatient market.
Executives
Michael M Goldberg director C/O MONTAUR CAPITAL PARTNERS, 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Uri Landesman 10 percent owner 230 PARK AVENUE, NEW YORK NY 10169
Platinum Partners Value Arbitrage Fund, Lp 10 percent owner 250 WEST 55TH STREET, 14TH FLOOR, NEW YORK NY 10019
Mark Nordlicht 10 percent owner 250 WEST 55TH STREET, NEW YORK NY 10019
Platinum Management (ny) Llc 10 percent owner 250 WEST 55TH STREET, NEW YORK NY 10019
Platinum-montaur Life Sciences, Llc 10 percent owner 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Platinum Partners Liquid Opportunity Master Fund L.p. 10 percent owner 152 WEST 57 STREET, 4TH FLOOR, NEW YORK NY 10019
Platinum Liquid Opportunity Management (ny) Llc 10 percent owner 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Bernhardt Charles Thomas Iii officer: Interim CFO 23 BIRCH ROAD, MALVERN PA 19355
Vincent D Enright director ONE CORPORATE CENTER, RYE NY 10580
William Grieco director 830 CRESCENT CENTRE DRIVE, SUITE 610, FRANKLIN TN 37067
Platinum Long Term Growth Vii, Llc 10 percent owner 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Robert F Doman director, officer: EXEC. CHAIRMAN AND INTERIM CEO C/O DUSA PHARMACEUTICALS, INC., 25 UPTON DRIVE, WILMINGTON MA 01887
Patrick T Mooney director, officer: CEO AND PRESIDENT C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
Christopher P. Schnittker officer: CFO 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540

Echo Therapeutics (Echo Therapeutics) Headlines

No Headlines